Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors

Inclusion Criteria:

Have a diagnosis of stage I-III breast cancer
Report worst level of fatigue in the past week as moderate to severe (i.e., a score >= 4 on a 0-10 scale, Screening Measures, question 1)
Have completed surgery, radiation, and/or chemotherapy, at least 2 or more months prior to enrollment (participants can be receiving maintenance, targeted or hormonal therapy)
Able to read and speak English
Currently not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception, i.e, abstinence, IUD (intrauterine device), hormonal contraceptive (birth control pills) or barrier method (condoms) prior to study entry and for the duration of study participation
Be capable of providing written informed consent

Exclusion Criteria:

Be currently taking any medications that contain bupropion (e.g., Wellbutrin, Forfivo, Aplenzin, or Zyban
Be taking a monoamine oxidase inhibitor (MAOI), linezolid, or methylene blue within 2 weeks prior to enrollment
Be taking any anti-psychotic medications within a week prior to enrollment
Have a history of renal impairment (i.e., glomerular filtration rate < 45)
Have a history of cirrhosis (i.e., Child-Pugh score >= 5)
Have a history of seizures
Have a history of bulimia or anorexia nervosa
Report a history of sensitivity to bupropion
Report an allergy to lactose
Have a psychiatric or neurological disorder that would interfere with study participation per physician or physician's designee